S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:SAVA

Cassava Sciences Stock Forecast, Price & News

$53.49
-1.13 (-2.07%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
$49.62
$55.89
50-Day Range
$43.13
$90.91
52-Week Range
$6.70
$146.16
Volume
2.18 million shs
Average Volume
5.83 million shs
Market Capitalization
$2.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.48
30 days | 90 days | 365 days | Advanced Chart
Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.


Cassava Sciences logo

About Cassava Sciences

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
11
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.62 per share

Profitability

Net Income
$-6.33 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
36,174,000
Market Cap
$2.14 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/22/2022

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

911th out of 1,390 stocks

Pharmaceutical Preparations Industry

434th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

Is Cassava Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cassava Sciences stock.
View analyst ratings for Cassava Sciences
or view top-rated stocks.

How has Cassava Sciences' stock been impacted by COVID-19?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SAVA stock has increased by 1,161.6% and is now trading at $53.49.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Cassava Sciences?

Cassava Sciences saw a drop in short interest in November. As of November 15th, there was short interest totaling 8,380,000 shares, a drop of 26.2% from the October 31st total of 11,350,000 shares. Based on an average daily volume of 8,630,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 22.5% of the shares of the company are short sold.
View Cassava Sciences' Short Interest
.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Cassava Sciences
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.09.
View Cassava Sciences' earnings history
.

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

4 Wall Street analysts have issued 1 year target prices for Cassava Sciences' stock. Their forecasts range from $100.00 to $215.00. On average, they expect Cassava Sciences' share price to reach $146.00 in the next year. This suggests a possible upside of 172.9% from the stock's current price.
View analysts' price targets for Cassava Sciences
or view top-rated stocks among Wall Street analysts.

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Remi Barbier, Chairman, President & Chief Executive Officer
  • Nadav Friedmann, Director, Chief Operating & Medical Officer
  • Eric J. Schoen, Chief Financial Officer
  • James W. Kupiec, Chief Clinical Development Officer
  • Michael Zamloot, Senior Vice President-Technical Operations

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.51%), Jane Street Group LLC (0.00%), Geode Capital Management LLC (1.60%), Citadel Advisors LLC (0.00%), Granite Point Capital Management L.P. (0.00%) and Morgan Stanley (0.89%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences
.

Which institutional investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Russell Investments Group Ltd., Rhenman & Partners Asset Management AB, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Alliancebernstein L.P., and New York State Common Retirement Fund.
View insider buying and selling activity for Cassava Sciences
or view top insider-selling stocks.

Which institutional investors are buying Cassava Sciences stock?

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Jane Street Group LLC, Citadel Advisors LLC, Sculptor Capital LP, Voloridge Investment Management LLC, IMC Chicago LLC, Morgan Stanley, and BlackRock Inc.. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences
or or view top insider-buying stocks.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $53.49.

How much money does Cassava Sciences make?

Cassava Sciences has a market capitalization of $2.14 billion. The company earns $-6.33 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Cassava Sciences have?

Cassava Sciences employs 11 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is www.cassavasciences.com.

Where are Cassava Sciences' headquarters?

Cassava Sciences is headquartered at 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at (512) 501-2444, via email at [email protected], or via fax at 512-501-0414.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.